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Abstract
Background
Trachoma is a blinding disease, initiated in early childhood by repeated conjunctival infec-
tion with the obligate intracellular bacterium Chlamydia trachomatis. The population preva-
lence of the clinical signs of active trachoma; ‘‘follicular conjunctivitis” (TF) and/or ‘‘intense
papillary inflammation” (TI), guide programmatic decisions regarding the initiation and ces-
sation of mass drug administration (MDA). However, the persistence of TF following resolu-
tion of infection at both the individual and population level raises concerns over the
suitability of this clinical sign as a marker for C. trachomatis infection.
Methodology/Principle Findings
We systematically reviewed the literature for population-based studies and those including
randomly selected individuals, which reported the prevalence of the clinical signs of active
trachoma and ocular C. trachomatis infection by nucleic acid amplification test. We per-
formed a meta-analysis to assess the relationship between active trachoma and C. tracho-
matis infection before and after MDA. TF and C. trachomatis infection were strongly
correlated prior to MDA (r = 0.92, 95%CI 0.83 to 0.96, p<0.0001); the relationship was simi-
lar when the analysis was limited to children. A moderate correlation was found between TI
and prevalence of infection. Following MDA, the relationship between TF and infection
prevalence was weaker (r = 0.60, 95%CI 0.25 to 0.81, p = 0.003) and there was no correla-
tion between TI and C. trachomatis infection.
Conclusions/Significance
Prior to MDA, TF is a good indicator of the community prevalence of C. trachomatis infec-
tion. Following MDA, the prevalence of TF tends to overestimate the underlying infection
prevalence. In order to prevent unnecessary additional rounds of MDA and to accurately
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ascertain when elimination goals have been reached, a cost-effective test for C. trachoma-
tis that can be administered in low-resource settings remains desirable.
Author Summary
Trachoma is the leading infectious cause of blindness worldwide, caused by the bacterium
Chlamydia trachomatis. Repeated infection of the conjunctiva during childhood can initi-
ate chronic conjunctival inflammation. This can lead to conjunctival scarring, in turning
of the eyelashes, abrasion of the eyelashes on the cornea and eventually blindness later in
adulthood. TheWorld Health Organization recommendsmass drug administration
(MDA) for infection control when the prevalence of the clinical sign of Active Trachoma
(TF) is10% in 1–9 year olds. This systematic review of the literature examined the rela-
tionship between TF and C. trachomatis infection before and after MDA in order to evalu-
ate the usefulness of TF for guiding trachoma control programmes. The population
prevalence of TF and C. trachomatis infectionwere strongly correlated prior to MDA,
however the relationship was weaker after MDA with a greater tendency for TF to overes-
timate the underlying infection prevalence. A cost effective test for C. trachomatis suitable
for use in low resource settings could prevent unnecessary additional rounds of MDA in
the population and could identify when trachoma elimination goals have been reached at
an earlier time point.
Introduction
Sight loss from trachoma is the end result of a scarring disease process that is initiated in early
childhoodby the obligate intracellular bacteriumChlamydia trachomatis [1]. Repeated infec-
tion of the conjunctiva by C. trachomatis causes a recurrent chronic follicular conjunctivitis
(TF) of the upper eyelid mucosal surface (Fig 1) [2]. This can sometimes be particularly severe
with intense papillary inflammation (TI). Together, TF and / or TI are collectively referred to
Fig 1. The natural history of an episode of ocular C. trachomatis infection and the associated conjunctival inflammatory response.
Trachomatous Inflammation–Follicular (TF): the presence of five or more follicles in the upper tarsal conjunctiva. Trachomatous Inflammation–Intense
(TI): pronounced inflammatory thickening of the upper tarsal conjunctiva that obscures more than half of the normal deep tarsal vessels [2].
doi:10.1371/journal.pntd.0005080.g001
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as “Active Trachoma”. Conjunctival scarring gradually develops, usually becoming visible from
early adulthood. Eventually the scarring causes the eyelashes to turn in and scratch the surface
of the eye. If left uncorrected, trichiasis traumatises the cornea surface, resulting in opacifica-
tion and sight loss.
There is a variable relationship between the clinical signs of Active Trachoma and the pres-
ence of C. trachomatis infection. The natural history of an infection episode in children is prob-
ably characterised by a brief “pre-clinical” phase, in which there is detectable infection but the
clinical signs of the inflammatory response are yet to develop (Fig 1). Human volunteer experi-
ments in which the conjunctiva was inoculatedwith C. trachomatis indicated that the signs of
disease typically take about 10 days to develop in previously uninfected individuals [3]. This is
followed by a variable period of time in which both infection and disease can be detected at the
same time; this may last for several days to many weeks. The immune response brings the
infection under control, completely clearing it or reducing it to undetectable levels. However,
inflammatory clinical signs persist, typically lasting several weeks after the resolution of the
infection. In children aged 4–15 years, data from longitudinal cohort studies estimate the
median duration of infection range between 23 days and 8 weeks, and the median duration of
disease between 54 days and 18 weeks [4–6]. The duration of disease and infection declines
with increasing age. Therefore, at an individual level there is frequently a large mismatch
betweenwhen infection can be detected and the clinical signs of disease are found [7].
The most recent estimates from theWorld Health Organization (WHO) Alliance for the
Global Elimination of Trachoma by 2020 (GET2020) estimates indicate that about 200 million
people live in trachoma endemic areas in 42 countries, 2.2 million have visual impairment or
blindness, and about 3.2 million have trichiasis [8]. To meet this large public health challenge,
the GET2020 Alliance recommends the implementation of the SAFE Strategy which tackles
the disease at different stages: Surgery to correct trichiasis,Antibiotics to treat chlamydial
infection and Facial cleanliness and Environmental improvements to suppress transmission of
the infection [1].
The antibiotic azithromycin is being used in community-widemass drug administration
(MDA); it is given as a single oral dose on an annual basis in endemic districts. Decisions
around when to initiate and stop MDA are guided by the prevalence of TF in children in
endemic communities. According to the current guidelines, azithromycin MDA is indicated
for entire districts where the prevalence of TF in 1–9 year olds is10%. Moreover, the determi-
nation of whether a program has controlled the active stage of trachoma as a public health
problem also rests on the district level prevalence of TF [9].
Therefore, in view of the significance attached to TF for making programmatic decisions, it
is important to understand the relationship between active disease and chlamydial infection in
endemic communities. It is probable that this relationship changes after the introduction of
MDA and will vary with different levels of endemicity. Several studies have specifically investi-
gated what clinical signs can tell us about infection [7, 10–19]. However, in addition there are
many other population-based studies, which report on both disease and infection, that can
contribute information. Here we systematically review the published literature for reports that
can inform our understanding of the relationship between clinical signs of active disease and C.
trachomatis infection, both before and after the introduction of MDA.
Methods
In this reviewwe included population-based studies and studies involving a random selection
of participants that report the relationship between signs of Active Trachoma (TF, TI, TF/TI)
and the detection of ocularC. trachomatis by nucleic acid amplification tests (NAAT),
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including polymerase chain reaction (PCR), polymerase chain reaction/enzyme immunoassay
(PCR-EIA), ligase chain reaction (LCR) and transcription-mediated amplification (TMA).We
excluded studies which did not test individuals without Active Trachoma for infection. Refer-
ences were identified through searching PubMed for articles using the terms (i) “trachoma”
AND “Chlamydia trachomatis”, (ii) “Trachoma” AND “PCR”, (iii) “Trachoma” AND “LCR”,
(iv) “Trachoma” AND “azithromycin”. The search was limited to 1991 onwards, the year of
the first report of the use of PCR to test for ocularC. trachomatis infection in a trachoma
endemic population [20]. The search was last updated on 5th May 2016.
The titles and abstracts of all articles resulting from these searches were screened by two
authors (AMR,MJB) for potentially eligible publications. These two authors then indepen-
dently assessed the potentially eligible articles for inclusion and extracted the data. The bibliog-
raphies of publications meeting the inclusion criteria were also reviewed for any additional
publications not already identified. Studies were excluded where the participant sample was
not population-based. Several studies were identifiedwith multiple related published reports
arising from the same data. These are considered as a single study, but for completeness we
include all the relevant references.
Core information was extracted using a standardised form. The core information included
country, year of publication, study design, study population size, age group, TF prevalence, TI
prevalence, TF/TI prevalence (if TF alone was not reported),C. trachomatis infection preva-
lence, diagnostic test used, grading system, use of antibiotic for infection control. The clinical
grading system was recorded: the 1981 DetailedWHO FPC System or the 1987 Simplified
WHO Trachoma Grading System [2, 21]. For the purpose of this review the prevalence levels
of TF in the populations studied were categorised as follows: Hypoendemic<10%, Mesoen-
demic 10–20% and Hyperendemic>20% [12].
Due to the heterogeneity in the study designs and the reporting of data, only a limited meta-
analysis was performed. Studies report the results for different age groups. Where available we
separately present both the “All Age” results and those for children (15 years). In the meta-
analysis we use the results from children only where these are available; where these are not
available, the all age results are used. Summary graphs are presented of the relationship
between: (i) the community prevalence of disease signs and C. trachomatis infection, (ii) the
sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) of TF
for infection, by the community prevalence of disease signs. The degree of correlation between
these was tested using Pearson’s correlation coefficient,weighted by study size. The relation-
ship between signs and infectionwas analysed separately for pre-treatment and post-treatment
data, then a test for interaction was performed on the two datasets combined to test whether
the association between signs and infectionwas similar in the pre and post-treatment data. For-
est plots were generated to illustrate the strength and heterogeneity of the relationship between
disease signs and detection of infection; study heterogeneity was estimated using the I2 statistic.
Hierarchical summary receiver operating characteristics (HSROC) curveswere plotted to illus-
trate the relationship between the sensitivity and specificity of signs of TF for the presence of C.
trachomatis infection and a pooled estimate of sensitivity and specificity was made in both the
pre and the post MDA studies. All analyses were performed using Stata 13. A Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and flow diagram
are included in the supporting information (S1 Checklist and S1 Fig).
Results
The search returned a list of 718 publications. The findings from pre and post-MDA studies
are presented separately. Thirty-six separate population-based studies reported findings prior
Active Trachoma and Ocular Chlamydia trachomatis Infection
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0005080 October 26, 2016 4 / 26
to the introduction of MDA. Several had multiple related publications; yielding a total of 48
publications (Table 1). Twenty-one studies reported findings following the introduction of
MDA met inclusion criteria, in a total of 35 publications (Table 2).
Pre-Treatment
Of the 36 pre-treatment study populations, 24 were hyperendemic, 8 mesoendemic and 4
hypoendemic (Table 1). The studies were conducted in populations from Tanzania (12), The
Gambia (7), Ethiopia (6), Nepal (4), Niger (3), Cameroon (1), Guinea Bissau (1), Egypt (1) and
Australia (1). The SimplifiedWHO Trachoma Grading System was used in 28 studies and 8
used the DetailedWHO FPC System. The majority of studies (25) used the commercially pro-
ducedAmplicor CT/NG (Roche) PCR assay, five used ligase chain reaction (LCR, Abbott Labo-
ratories), and six used in-house PCR assays. Four of the 36 studies listed in Table 1 did not
report the community prevalence of C. trachomatis infection, however they report infection on
a selected subset of individuals [11, 22–24]. These four studies were therefore retained in
Table 1 as they contribute useful information, however they were excluded from the meta-anal-
ysis. Of the remaining 32 studies included in the meta-analysis, 29 studies reported data for
childhood age groups (variable age ranges), seven of which also reported all age data, and three
studies reported only all age data.
Prior to the introduction of MDA there was evidence of a strong positive correlation
between the community-level prevalence of Active Trachoma and the community-level preva-
lence of detectedC. trachomatis, using data from all 32 studies (r = 0.92, 95%CI 0.83 to 0.96,
p<0.0001), Fig 2A. The correlation was similar when the analysis was limited to children only
data (29 studies; r = 0.91, 95%CI 0.82 to 0.96, p<0.0001). The correlation was much weaker for
all age data (10 studies; r = 0.51, 95%CI -0.18 to 0.86 p = 0.13). Overall, the community preva-
lence of TF is typically greater than the underlying community prevalence of detectedC. tra-
chomatis, with TF having a higher prevalence than C. trachomatis in 25 out of the 32 studies.
The mean difference in prevalence was 10.4% (95% CI 5.9%-15.0%, p = 0.001).
There were 19 studies that reported the prevalence of TI separately from TF. There was evi-
dence of a moderate positive correlation between the community-level prevalence of TI and
the community-level prevalence of detectedC. trachomatis (r = 0.75, 95%CI 0.45 to 0.90
p = 0.0002), Fig 2B. Although there are only a limited number of studies, in all communities
where the TI prevalence was>20% the prevalence of C. trachomatis was at least 30%. In con-
trast, where the TI prevalence was below 20% there was a considerable degree of variation in
the underlying community prevalence of infection.
There was sufficient data at the individual level presented to estimate the sensitivity, speci-
ficity, PPV and NPV for 21 studies. The sensitivity of TF for identifying the presence of C. tra-
chomatis infection varied substantially with the prevalence of TF in the community, Fig 3A.
There was evidence of a strong positive correlation (r = 0.82, 95%CI 0.59 to 0.92, p<0.0001). In
contrast, there was a strong negative correlation between the specificity of TF for infection and
the community prevalence of TF (r = -0.92, 95%CI -0.97 to -0.80, p<0.0001), Fig 3B. The For-
est plot of the pre-treatment relationship between disease and detection of infection at the indi-
vidual level showed an overall strong association (OR 6.05, 95% CI 5.49 to 6.67, p<0.0001),
although there was marked heterogeneity (I2 = 87.1%, p<0.001), Fig 4A. A plot of sensitivity
against specificity of the pre-treatment studies using TF as a test for C. trachomatis infection at
the individual level showed that the overall estimated sensitivity was moderate (57.1% (45.4–
68.1%) and the overall specificitywas good (81.1% (73.4–87.0%), Fig 5A.
The relationship between the community-level prevalence of Active Trachoma and the pro-
portion of people with TF who were infected with C. trachomatis (Positive Predictive Value,
Active Trachoma and Ocular Chlamydia trachomatis Infection
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Table 1. Active Trachoma and Chlamydia trachomatis (Ct) infection prior to mass antibiotic treatment.
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
1991, [20]
Baseline cross-sectional
population-based data for a
treatment trial. One child aged
1–7 years was randomly
selected from 234 households
in a village.
1–7 years:
234
1–7 years:
● TF/TI 58.5%
(137/234
● TI 15.8%
(37/234)
1–7 years:
47.9% (112/
234)
1–7 years:
65.0% (89/
137)
1–7 years:
23.7% (23/
97)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: in-house
PCR-EIA for OMP1.
Gambia,
1994, [29]
Cross-section survey of the
entire population of two
villages
● All ages:
1332
● 0–15
years: 714
All ages:
● TF/TI 15.0%
(200/1332)0–
15 years:
● TF/TI 29.8%
(183/714)
● All ages:
17.2% (229/
1332)
● 0–15 years:
29.8% (183/
714)
● All ages:
72.0%
(144/200)
● 0–15
years:
73.2%%
(134/183)
● All ages:
7.5% (85/
1132)
● 0–15
years:
9.2% (49/
531)
● Mesoendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: in-house
PCR for plasmid, detected
by agarose gel
electrophoresis.
Gambia,
1994, [22]
Cross-section survey of the
entire population of one
village. Only 133 individuals
were tested for Ct infection by
PCR. All active cases were
tested. A sample of 37 normal
individuals from two
households were tested.
All ages: 844 All ages:
● TF/TI 11.4%
(96/844)
Data not
available
All ages:
51.0% (49/
96)
All ages:
5.4% (2/
37)
● Mesoendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: in-house
PCR for plasmid, detected
by agarose gel
electrophoresis.
● The clinically normal group
are not necessarily
representative of the whole
community as they are
drawn from two households
only.
Nepal, 1998,
[30]
All children under 11 years in
primary school and all children
from four randomly selected
households.
0–10 years:
70
0–10 years:
● TF/TI 38.6%
(27/70)
● TI 7.1% (5/
70)
0–10 years:
57.1% (40/70)
0–10
years:
66.7% (18/
27)
0–10
years:
51.2% (22/
43)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: in-house
PCR for OMP1.
● The sample was not
necessarily representative of
the child population of this
community.
Egypt, 1999,
[10, 31]
Baseline cross-sectional,
population-based survey; pre-
treatment data from a RCT of
azithromycin vs tetracycline.
● All ages:
2069
● 1–10
years: 731
All ages:
● TF/TI 19.7%
(408/2069)
● TI 5.8%
(120/2069)
● 1–10 years:
TF/TI 48.3%
(353/731)
● TI 13.0%
(95/731)
● All ages:
35.7% (739/
2069)
● 1–10 years:
48.6% (355/
731)
● All ages:
66.9%
(273/408)
● 1–10
years:
69.4%
(245/353)
● All ages:
31.6%
(466/1661)
● 1–10
years:
29.1%
(110/378)
● Hyperendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: LCR,
Abbott Laboratories.
Gambia,
1999, [31]
Baseline cross-sectional,
population-based survey; pre-
treatment data from a RCT of
azithromycin vs tetracycline.
● All ages:
1747
● 0–10
years: 730
All ages:
● TF/TI 15.8%
(277/1747)
● TI 7.0%
(122/1747)0–
10 years:
● TF/TI 33.8%
(247/730)
● TI 13.7%
(100*/730)
● All ages:
35.9% (628/
1747)
● 0–10 years:
39.3% (287/
730)
All ages:
59.9%
(166/277)
All ages:
31.4%
(462/1470)
● Hyperendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: LCR,
Abbott Laboratories.
● Main results presented for
all ages, possible to derive
some of the indicators for the
0–10 year group.
(Continued )
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Table 1. (Continued)
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
1999, [31]
Baseline cross-sectional,
population-based pre-
treatment survey; data from a
RCT of azithromycin vs
tetracycline.
● All ages:
2653
● 0–10
years: 940
All ages:
● TF/TI 31.8%
(844/2653)
● TI 16.4%
(436/2653)
0–10 years:
● TF/TI 60.1%
(565/940)
● TI 24.7%
(233*/940)
● All ages:
18.5% (491/
2653)
● 0–10 years:
34.6% (325/
940)
All ages:
48.3%
(408/844)
All ages:
4.6% (83/
1809)
● Hyperendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: LCR,
Abbott Laboratories.
● Main results presented for
all ages, possible to derive
some of the indicators for the
0–10 year group.
● In this study there was
some concern about sample
degradation, leading to an
underestimate of infection
Nepal, 1999,
[11]
Cross-sectional survey of all
children in six villages. Swabs
and LCR test done on all
active cases and 1/8 without
active disease.
0–10 years:
726
years:
● TF/TI 6.3%
(46/726)
0–10 years:
0%(0/90)
0–10
years: 0%
(0/46)
0–10
years: 0%
(0/44)
● Hypoendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: LCR,
Abbott Laboratories.
Nepal, 2001,
[23]
Baseline cross-sectional
population-based data from a
RCT of mass vs targeted
antibiotic treatment. Children
recruited from 17 wards. Only
the children with active
disease and a similar sized
random sample of the others
were tested by LCR.
1–7 years:
619
1–7 years:
● TF/TI 19.0%
(118/619)
Data not
available
1–7 years:
24.8% (29/
117)
1–7 years:
4.2% (5/
118)
● Mesoendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: LCR,
Abbott Laboratories.
Gambia,
2003, [7, 27,
32, 33]
Baseline population-based
survey of a longitudinal study
of MDA. All residents of 14
villages.
● All ages:
1319
● 1–9 years:
492
All ages:
● TF/TI 7.8%
(103/1319)
● TI 1.4% 19/
13191–9
years:
● TF 16.3%
(80/492)
● TI 2.6% (13/
492)
● All ages:
7.2% (95/1319)
● 1–9 years:
9.3% (46/492)
● All ages:
22.3% (23/
103)
● 1–9
years:
23.8% (19/
80)
● All ages:
5.9% (72/
1216)
● 1–9
years:
6.6% (27/
412)
● Mesoendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: Amplicor
PCR, Roche.
Tanzania,
2003, [27, 34,
35]
Baseline population-based
survey for a longitudinal study
of MDA. All residents of a
single sub-village.
All ages: 956 All ages:
● TF/TI 18.2%
(174/956)
● TI 11.6%
(111/956)
All ages: 9.5%
(91/956)
All ages:
33.3% (58/
174)
All ages:
4.2% (33/
782)
● Hyperendemic Setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2003, [27,
36–39]
Baseline population-based
survey for a longitudinal study
of MDA. All residents of a
single village.
● All ages:
871
● 0–10
Years: 325
All ages:
● TF/TI 35.8%
(312/871)
● TI 10.9%
(95/871)
● 0–10 Years:
F/TI 72.6%
(236*/325)
● All ages:
56.9% (496/
871)
● 0–10 Years:
64.9% (211*/
325)
All ages:
77.2%
(241/312)
All ages:
45.6%
(255/559)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2004, [17]
Random selection of 100
children aged 1–6 years from
four villages.
1–6 years:
100
1–6 years:
● TF 79% (79/
100)
● TI 55% (55/
100)
1–6 years:
63.0% (63/100)
1–6 years:
72.2% (57/
79)
1–6 years:
28.6% (6/
21)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
(Continued )
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Table 1. (Continued)
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Gambia,
2006, [40]
Cross-sectional population-
based study of school children
aged 4–15 years from nine
villages.
4–15 years:
331
4–15 years:
● TF 18.2%
(60/331)
● TI 1.5% (5/
331)
4–15 years:
21.8% (72/331)
4–15
years:
41.7% (25/
60)
4–15
years:
15.3% (38/
249)
● Mesoendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: in-house
RT-PCR assay for
chlamydial 16S rRNA
Tanzania,
2006a, [41]
Cross-sectional population-
based study of children aged
1–9 years from two
hyperendemic villages.
1–9 years:
464
1–9 years:
● TF 44.0%
(204/464)
1–9 years:
24.8% (115/
464)
1–9 years:
36.3% (74/
204)
1–9 years:
13.6% (41/
301)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2006b, [41]
Cross-sectional population-
based study of children aged
1–9 years from one
hypoendemic village.
1–9 years:
200
1–9 years:
● TF 12.5%
(25/200)
1–9 years:
6.5% (13/200)
1–9 years:
32.0% (8/
25)
1–9 years:
2.9% (5/
175)
● Hypoendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Niger, 2007,
[42]
Cross-sectional study of
randomly selected children
from 12 villages.
1–5 years:
651
1–5years:
● TF/TI 43.0%
(280*/651)
● TI 16%
(104*/651)
1–5years:
21.0% (137*/
651)
1–5years:
37.3%
(103*/267)
1–5years:
9.0% (33*/
365)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2007, [43]
Cross-sectional population-
based study of children aged
0–10 years from two
hyperendemic villages.
0–10 years:
56
0–10 years:
● TF/TI 78.6%
(44/56)
● TI 46.4%
(26/56)
0–10 years:
39.3% (22/56)
0–10
years:
43.1% (19/
44)
0–10
years:
25.0% (3/
12)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Nepal, 2008,
[44]
Cross-sectional study of 9
randomly selected households
from one village
All ages: 127 All ages:
● TF 26.8%
(34/127)
● TI 38.6%
(49/127)
All ages:
38.6% (49/127)
All ages:
44.1% (15/
34)
All ages:
36.6% (34/
93)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Gambia,
2009, [45, 46]
Cross-sectional survey using
a two-stage cluster random
sampling strategy with
probability of selection
proportional to size, in 19
enumeration areas in Lower
River Region, The Gambia.
1–9 years:
876
1–9 years:
● TF 12.3%
(108/876)
● TI 0.1% (1/
876)
1–9 years:
0.3% (3/876)
1–9 years:
0.9% (1/
108)
1–9 years:
0.3% (2/
768)
● Mesoendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2009, [47]
Cross-sectional population-
based sample of 8 randomly
selected children (1–5 years)
per village from eight villages.
1–5 years:
120
1–5 years:
● TF/TI 60.8%
(73/120)
● TI 44.2%
(53/120)
1–5 years:
40.8% (49/120)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2010, [18, 48]
Cross-sectional population-
based sample of children (1–5
years) living in 24 villages.
1–5 years:
1200
1–5 years:
● TF/TI 86.0%
(mean village
prevalence)
1–5 years:
52.9% (mean
village
prevalence)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
● NB: The data are reported
a mean of the prevalence
across all 24 villages.
Gambia,
2010, [25, 49]
Cross-sectional population-
based survey of ~100
randomly selected children
aged 0–5 years from 48
enumeration areas.
0–5 years:
5033
0–5 years:
● TF 6.3%
(316/5033)
● TI 0.6% (28/
5033)
0–5 years:
0.8% (39/5033)
0–5 years:
0.9% (3/
316)
0–5 years:
0.7% (36/
4717)
● Hypoendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche.
(Continued)
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Table 1. (Continued)
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
2010, [49–
51]
Cross-sectional population-
based survey of ~100
randomly selected children
aged 0–5 years from 32
enumeration areas. The
villages were purposely
selected based on having a
preliminary survey prevalence
of >20%.
0–5 years:
3122
0–5 years:
● TF 30.8%
(963/3122)
● cTI 7.8%
(244/3122)
0–5 years:
21.9% (684/
3122)
0–5 years:
48.9%
(471/963)
0–5 years:
9.8% (213/
2159)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche.
Niger, 2010,
[52]
Cross-sectional study of
randomly selected children
from 12 villages
1–5 years:
557
1–5 years:
● TF/TI 41.6%
(232/557)
1–5 years:
20.1% (112/
557)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Australia,
2011, [14]
Population-based cross-
sectional study in five
Aboriginal communities.
All ages:
1282
All ages:
● TF 8.4%
(108/1282)
All ages: 3.6%
(46/1282)
All ages:
17.6% (19/
108)
All ages:
2.3% (27/
1174)
● Hypoendemic setting
● Clinical grading: variation
of the detailed WHO-FPC
system [14]
● Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2011, [26, 53]
Cross-sectional population-
based survey in three villages
0–9 years:
473
0–9 years:
● TF 13.7%
(65/473)
● TI 1.3% (6/
473)
0–9 years:
5.3% (25/473)
0–9 years:
6.1% (4/
65)
0–9 years:
5.1% (21/
408)
● Mesoendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: Amplicor
PCR, Roche.
Tanzania,
2011, [54, 55]
Cross-sectional baseline
population-based survey in 4
villages.
0–8 years:
1991
0–8 years:
● TF 27.8%
(553/1991)
0–8 years:
23.7% (463/
1956)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2011, [56]
Cross-sectional baseline,
population-based survey of
four communities
0–9 years:
2118
0–9 years:
● TF/TI 27.7%:
(586/2118)
0–9 years:
23.6% (499/
2118)
0–9 years:
33.1%
(194*/586)
0–9 years:
13.6%
(209/1532)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2011, [57]
Cross-sectional population-
based survey in 23
communities. Both arms of a
cluster RCT at baseline.
0–9 years:
1168
0–9 years:
● TF/TI 66.5%
(770/1158)
0–9 years:
44.7% (516/
1168)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2012, [19, 58,
59]
Cross-sectional baseline,
population-based survey of
0–9 year olds in 12
communities
0–9 years:
583
0–9 years:
● TF/TI 68.3%
(393/575)
0–9 years:
42.4% (248/
584)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Cameroon,
2012, [24]
Cross-sectional study, with a
random selection of children
from 30 villages, with
probability proportional to size.
Only children with signs of
Active Trachoma were tested
for infection by PCR.
1–9 years:
2397
0–9 years:
● TF/TI 26.2%
(628/2397)
● TI 5.2%
(124/2397)
Data not
available
0–9 years:
35.0%
(220*/628)
Data not
available
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: in-house
PCR assay for chlamydial
rRNA gene.
Niger, 2012,
[60, 61]
Cross-sectional study for
randomly selected children
from 48 communities.
0–5 years:
4484
0-5years:
● TF 26.0%
(1166*/4484)
0-5years:
20.7% (928*/
4484)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
(Continued )
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PPV) showed a positive correlation (r = 0.80, 95%CI 0.56 to 0.91, p<0.0001), Fig 3C. The pat-
tern of this distribution suggests that when the community-level prevalence of TF is below 20%
the PPV of TF for the presence of C. trachomatis infection drops substantially. Above a com-
munity-level prevalence of TF of 20% the PPV is typically 40–70%, across a wide range of TF
prevalence.
The relationship between the community-level prevalence of Active Trachoma and the pro-
portion of people without TF who were not infected with C. trachomatis (Negative Predictive
Value, NPV) showed a strong negative correlation (r = -0.81, 95%CI -0.92 to -0.57, p<0.0001),
Fig 3D.When the community-level TF prevalence was greater than 20%, the NPV was more
variable.
Post-Treatment
Of the 21 studies from populations following the introduction of MDA, prior to the first treat-
ment, 15 were hyperendemic, 3 mesoendemic and 3 hypoendemic (Table 2). The studies were
conducted in populations from Tanzania (10), Ethiopia (5), The Gambia (3), Nepal (2), and
Egypt (1). The SimplifiedWHO Trachoma Grading System was used in 17 studies and four
used the DetailedWHO FPC System. The majority of studies (15) used the Amplicor CT/NG
(Roche) PCR assay, four used LCR (Abbott), one used an in-house PCR and one used the
Aptima Combo2 (Hologic) TMA assay. There was one study included in Table 2 that did not
report the community prevalence of C. trachomatis infection, and was therefore not included
in the meta-analysis [23]. One of the Gambian studies involved surveys in four separate dis-
tricts; we have included these as four separate sets of data in the analysis [25]. This resulted in
23 discrete studies included in the meta-analysis: for 20 studies data was available on children
only (variable age ranges), two of which also reported all age data, and three other studies
reported only all age data.
Table 1. (Continued)
Country,
Year, Ref.
Study design Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Guinea
Bissau, 2013,
[62, 63]
Cross-sectional population-
based survey across multiple
communities
● All ages:
1508
● 1–9 years:
618
All ages:
● TF/TI 11.1%
(167/1508)
● TI 2.0% (29/
1508)1–9
years:
● TF/TI 22.0%
(136/618)
● TI 3.2% (21/
618)
● All ages:
17.9% (269/
1507)
● 1–9 years:
25.4% (157/
618)
● All ages:
63.3%
(100/158)
● 1–9
years: 86/
129
(66.7%)
● All ages:
12.1%
(164/1351)
● 1–9
years: 83/
537
(15.5%)
● Mesoendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2013, [64]
Cross-sectional population-
based survey of children from
one village.
0–9 years: 27 0–9 years:
● TF 44.9%
(57/127)
● TI 16.5%
(21/127)
0–9 years:
27.6% (35/127)
0–9 years:
29/57
(50.9%)
0–9 years:
6/70
(8.6%)
● Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche.
Tanzania,
2014, [65]
Cross-sectional population-
based survey of all 1–6 year
olds in a single village
1–6 years:
208
1–6 years:
● TF/TI 47.0%
(98/208)
1–6 years:
25.0% (52/208)
Data not
available
Data not
available
● .Hyperendemic setting
● Clinical grading: simplified
WHO system
● Chlamydia test: Amplicor
PCR, Roche.
* Estimated value inferred from available data in publication.
doi:10.1371/journal.pntd.0005080.t001
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Table 2. Active Trachoma and Chlamydia trachomatis (Ct) infection after the introduction of mass antibiotic treatment.
Country,
Year
Study design Time
Point
post 1st
MDA
Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
1993, [20,
66]
Cross-section survey of
randomly selected
children one month after
the completion of a one
month tetracycline
treatment course, given
as MDA to the entire
community.
1 month 1–7 years:
227
1–7 years:
● TF/TI
41.9% (95/
227)
● TI 2.6% (6/
227)
1–7 years:
23.8% (54/
227)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: in-house
PCR-EIA for OMP1.
Egypt, 2003,
[10, 31]
Cross-section
population-based survey
14 months after
azithromycin MDA.
14
months
1–10 years:
354
1–10 years:
● TF/TI
26.0% (92/
354)
1–10 years:
5.1% (18/354)
1–10
years:
9.8% (9/
92)
1–10
years:
3.4% (9/
262)
● Hyperendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: LCR,
Abbott Laboratories.
● Only the azithromycin
arm is included.
Gambia,
1999, [31]
Cross-section
population-based survey
12 months after
azithromycin MDA.
12
months
All ages:
● 675 (exam)
● 540
(tested)
All ages:
● TF/TI 8.6%
(58*/675)
● TI 2.2%
(15*/675)
All ages: 8.3%
(45/540)
Data not
available
Data not
available
● Hyperendemic setting,
pre treatment
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: LCR,
Abbott Laboratories.
● Only the azithromycin
arm is included.
Tanzania,
1999, [31]
Cross-section
population-based survey
12 months after
azithromycin MDA.
12
months
All ages:
● 1308
(exam)
● 1162
(tested)
All ages:
● TF/TI
24.6% (322*/
1308)
● TI 6.3%
(83*/1308)
All ages: 7.0%
(82/1162)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: LCR,
Abbott Laboratories.
● Only the azithromycin
arm is included.
Nepal, 2001,
[23]
Cross-section survey of
randomly selected
normal children and a
purposive sample of
children with Active
Trachoma, 6 months
after azithromycin MDA.
6 months 1–7 years:
● 5262
(exam)
● 394
(tested)
1–7 years:
● TF/TI 16%
(841*/5262)
Data not
available
1–7
years:
11.8%
(31/263)
1–7
years:
5.1% (6/
118)
● Mesoendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: LCR,
Abbott Laboratories.
Tanzania,
2004, [34,
35]
Cross-sectional survey of
all residents of a sub-
village, 24 months after
MDA
24
months
All ages: 842 All ages:
● TF/TI 5.8%
(49/842)
All ages: 0.1%
(1/842)
All ages:
2.0% (1/
49)
All ages:
0.0% (0/
793)
● Hyperendemic setting,
pre-treatment
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Gambia,
2005, [7, 27,
32, 33]
Cross-sectional survey of
all residents of 14 small
villages, 12 months after
MDA
12
months
● All ages:
1210
● 1–9 years:
440
All ages:
● TF/TI 3.9%
(47/1210)1–9
years:
● TF 6.8% 30/
440)
● TI 0.9% (4/
440)
● All ages:
2.3% (28/
1210)
● 1–9 years:
5.4% (24/440)
● All ages:
29.8%
(14/47)
● 1–9
years:
36.7%
(11/30)
● All ages:
1.2% (14/
1163)
● 1–9
years:
3.2% (13/
410)
● Mesoendemic setting,
pre-treatment
● Clinical grading: detailed
WHO-FPC system
● Chlamydia test: Amplicor
PCR, Roche.
Tanzania,
2005, [27,
36–39]
Cross-sectional survey of
residents of a village, 12
months after MDA
12
months
0–7 years:
287
0–7 years:
● TF/TI
46.8% (134*/
287)
0–7 years:
12.8% (37*/
287)
Data not
available
Data not
available
● Hyperendemic
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
(Continued )
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Table 2. (Continued)
Country,
Year
Study design Time
Point
post 1st
MDA
Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Tanzania,
2007, [39]
Cross-sectional of
population-based survey
5 years after baseline
MDA and 3.5 years after
a second MDA.
5 years 0–10 years:
464
0–10 years:
● TF 30.2%
(140/464)
● TI 10.6%
(49/464)
0–10 years:
25.9% (120/
464)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2008, [67]
Cross-sectional
population based sample
of children from 32
communities. These had
received between 1 and 3
rounds of MDA, with the
most recent does less
than 6 months in about
half the communities.
Variable 3–9 years:
1459
3–9 years:
● TF 23.6%
(345/1459)
3–9 years:
3.0% (44/
1459)
3–9
years:
6.1% (21/
345)
3–9
years:
6.1% (23/
1114)
● Hyperendemic setting
● Heterogeneous
treatment history
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2009, [47]
Cross-sectional
population-based sample
of 8 randomly selected
children (1–5 years) per
village from eight
villages. The villages had
received MDA biannually
for 2 years, with the last
dose 18 months prior to
the survey.
42
months
0–5 years:
120
0–5 years:
● TF/TI
47.5%: (57/
120)
● TI 30.0%
(36/120)
0–5 years:
15% (18/120)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Ethiopia,
2010, [18,
48]
Cross-sectional
population-based sample
of children (1–5 years)
living in 24 villages.
Communities had
received 4 biannual
MDA, the most recent 6
months before survey
24
months
1–5 years:
1234
1–5 years:
● TF/TI
39.2% (mean
village
prevalence)
1–5 years:
2.0% (mean
village
prevalence)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
● NB: The data are
reported a mean of the
prevalence across all 24
villages.
Tanzania,
2011, [15]
Cross-sectional
population-based sample
of children from 71
communities. All
communities had
received 3 to 7 rounds of
MDA.
Variable 0–5 years:
7817
0–5 years:
● TF 10.0%
(784/7817)
● TI 3.2%
(252/7817)
0–5 years:
5.5%% (429/
7817)
0–5
years:
23.5%
(184/784)
0–5
years:
3.5%
(245/
7033)
● Mesoendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Heterogeneous MDA
history. Wide range of
community level
prevalence of infection and
disease. Summary data
here pools these
communities
Ethiopia,
2011, [57]
Cross-sectional
population-based survey
in 24 communities. Both
arms of a cluster RCT of
latrine provision received
a single round of MDA at
baseline.
24
months
0–9 years:
1211
0–9 years:
● TF/TI
47.0% (567/
1207)
0–9 years:
14.6% (177/
1211)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
● Data from both arms
combined.
Ethiopia,
2012, [19,
58, 59, 68,
69]
Cross-sectional survey of
50 children per village
under 10 years in 12
villages. Three annual
rounds of MDA were
given. The final survey
was months after the last
MDA.
36
months
0–9 years:
577
0–9 years:
● TF 43.5%
(251/577)
0–9 years:
4.3% (25/577)
Data not
available
Data not
available
● Hyperendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
(Continued )
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Table 2. (Continued)
Country,
Year
Study design Time
Point
post 1st
MDA
Participants Active
Trachoma %
Ct % Ct+/TF+ Ct+/TF- Comments
Gambia,
2013, [25,
70]
Cross-sectional
population-based sample
of children from 48
communities enrolled in
an cluster RCT from four
districts. 24 communities
had 3 annual MDA and
24 communities had a
single round of MDA at
baseline. Survey was 3
years after the first round
of MDA.
36
months
0–5 years:
● District 1:
1128
● District 2:
1199
● District 3:
1243
● District 4:
1246
0–5 years:
● TF 0.2% (2/
1128)
● TF 0.3% (3/
1199)
● TF 3.8%
(47/1243)
● TF 6.4%
(80/1246)
0–5 years:
● 0.5% (6/
1128)
● 0.1% (1/
1198)
● 1.1% (13/
1241)
● 0.3% (4/
1235)
0–5
years:
● 0.0% (0/
2)
● 0.0% (0/
3)
● 6.4% (3/
47)
● 0.0% (0/
80)
0–5
years:
● 0.5% (6/
1126)
● 0.1% (1/
1196)
● 0.8%
(10/1196)
● 0.3% (4/
1166)
● Hypoendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche.
● Data from both trial arms
were combined, and
presented separately for
each district.
Tanzania,
2014, [51,
71]
Cross-sectional survey of
all children under 10
years in four villages.
Four annual rounds of
MDA were given. The
final survey was 6
months after the last
MDA.
42
months
0–9 years:
2234
0–9 years:
● TF/TI 7.9%
(176/2234)
0–9 years:
5.1% (114/
2234)
Data not
available
Data not
available
● Hyperendemic setting,
pre-treatment
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2014, [71,
72]
Cross-sectional
population-based sample
of children aged 0–5
years in 32 villages, 100
children per village.
Survey was done 12
months after the third
MDA.
36
months
0–5 years:
3136
0–5 years:
● TF 7.6%
(237/3136)
0–5 years:
4.5% (142*/
3136)
0–5
years:
29.5%
(70/237)
0–5
years:
2.5%
(72*/
2899)
● Hyperendemic setting,
pre-treatment
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Tanzania,:
2015,[73]
Cross-sectional
population-based of
residents of a village,
which had received 2
rounds of MDA 12 and 10
years previously.
12 years ● All ages:
571
● 1–9 years:
200
All ages:
● TF 2.5%
(14/571)1–9
years:
● TF 6.5%
(13/200)
● TI 1.5% (3/
200)
All ages: 0%
(0/571)1–9
years: 0% (0/
200)
Data not
available
Data not
available
● Hyperendemic setting,
pre-treatment
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Nepal, 2016,
[74]
Cross-section survey of
1–9 year olds in 24
randomly selected
communities. Four
rounds of MDA. The
survey was conducted 5
years after the first round.
5 years 1–9 years:
1124
1–9 years:
● TF/TI 0.3%
(3/1124)
1–9 years: 0%
(0/1124)
Data not
available
Data not
available
● Hypoendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Amplicor
PCR, Roche
Tanzania,
2016, [75]
Random sample of
children aged 1–9 years,
from 30 hamlets. 50
children were sampled
per hamlet. Communities
had received variable
rounds of MDA, between
4 and seven years
previously.
7 years 1–9 years:
1474
1–9 years:
● TF 0.4%
(6*/1474)
1–9 years:
1.1% (16/
1474)
Data not
available
Data not
available
● Hypoendemic setting
● Clinical grading:
simplified WHO system
● Chlamydia test: Aptima
Combo2, Hologic
* Estimated value inferred from available data in publication.
a Additional data sub-divided by district were provided by the authors of this study.
doi:10.1371/journal.pntd.0005080.t002
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Fig 2. The relationship between the prevalence of disease signs and infection before and after the
introduction of MDA. (a) Community prevalence of TF (or TF/TI) vs. the community prevalence of C. trachomatis
infection before the introduction of MDA. (b) Community prevalence of TI vs. the community prevalence of C.
trachomatis infection before the introduction of MDA. (c) Community prevalence of TF (or TF/TI) vs. the community
prevalence of C. trachomatis infection after the introduction of MDA. (d) Community prevalence of TI vs. the
community prevalence of C. trachomatis infection after the introduction of MDA. (e) Community prevalence of TF (or
TF/TI) vs. the community prevalence of C. trachomatis infection after the introduction of MDA, showing only the
communities with less than 15% TF. Data from population-based studies, summarised in Tables 1 and 2. The size of
the circles reflects the sample size. Line fitted by linear regression, weighted by the size of the studies.
doi:10.1371/journal.pntd.0005080.g002
Fig 3. The relationship between the individual level presence of Active Trachoma (TF or TF/TI) and the
detection of C. trachomatis infection by community TF prevalence before the introduction of MDA. (a)
Sensitivity of TF for infection. (b) Specificity of TF for infection. (c) Positive Predictive Value (PPV) of TF for C.
trachomatis infection. (d) Negative Predictive Value (NPV) of TF for C. trachomatis infection. Data from population-
based studies, summarised in Table 1. The size of the circles reflects the sample size. Line fitted by linear
regression, weighted by the size of the studies, except for the PPV which was fitted by polynomial.
doi:10.1371/journal.pntd.0005080.g003
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Following the introduction of MDA there was evidence of a moderate positive correlation
between the community-level prevalence of Active Trachoma and the community-level preva-
lence of detectedC. trachomatis, using data from all 23 studies (r = 0.60, 95%CI 0.25 to 0.81,
p = 0.003), Fig 2C. The relationship was similar when the analysis was limited to the 20 studies
of children only (r = 0.60, 95%CI 0.21 to 0.82, p = 0.005). However, for the five studies report-
ing results for all ages there was no significant correlation (r = 0.72, 95%CI -0.18 to 0.86
p = 0.18). The overall impression is that the relationship between disease and infection is more
uncertain post-MDA, such that the community-level prevalence of TF can substantially overes-
timate the underlying community-level prevalence of C. trachomatis; the community preva-
lence of TF can remain high (>20%) even when the prevalence of infection has declined
(<10%), Fig 2C and 2E.
Fig 4. A Forest plot showing the relationship between Active Trachoma (TF or TF/TI) and the detection of C.
trachomatis infection at the individual level (a) before and (b) after the introduction of MDA, grouped by
community TF prevalence level. Studies are ordered by increasing prevalence of TF, the size of the grey boxes
represent the how much weight each study contributes to the overall estimate, the blue diamonds represent the
subtotal and overall pooled odds ratio estimates. The odds ratios are for ocular C. trachomatis infection as the
outcome and TF as the explanatory variable.
doi:10.1371/journal.pntd.0005080.g004
Fig 5. Sensitivity versus specificity of each study, using TF to diagnose C. trachomatis infection at the individual
level (a) before and (b) after the introduction of MDA. Each circle represents the estimate for a single study, with
the size of the circle representing the size of the study. The red square is the estimated pooled sensitivity and
specificity for all studies (Pre- or Post-MDA). The orange dashed line represents the 95% CI (or confidence region
in 2 dimensions) for the sensitivity and specificity. The grey curve (hierarchical summary receiver operating
characteristic (HSROC) curve) represents the estimated relationship between sensitivity and specificity in these
studies, with the grey dashed line indicating the region in which we would expect 95% of studies to fall.
doi:10.1371/journal.pntd.0005080.g005
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We found evidence that the relationship between the prevalence of TF and the prevalence of
C. trachomatis infection differs between pre and post-MDA. Assuming a linear relationship
betweenC. trachomatis and TF, the prevalence of C. trachomatis was associated with an
expected 6.5% increase for every 10% increase in TF in pre-MDA studies, compared with an
increase of 2.8% in post-MDA (test for interaction p = 0.004).This demonstrates that as the
prevalence of TF increases, the expected increase in C. trachomatis is higher in pre-MDA com-
munities than in post-MDA communities.
There were only eight studies that reported the prevalence of TI separately from TF after the
introduction of MDA. There was no evidence of a correlation between the community-level
prevalence of TI and the community-level prevalence of detectedC. trachomatis (r = 0.50, 95%
CI -0.31 to 0.89 p = 0.20), Fig 2D. However, it is noteworthy that the prevalence of TI was low
(<10%) in all but two communities.
There was sufficient data presented to estimate the sensitivity, specificity, PPV and NPV
for only 10 studies at the individual level after introduction of MDA. Therefore, only limited
inference can be drawn. The sensitivity of TF for identifying the presence of C. trachomatis
infection after the introduction of MDA varied widely, across a range of community-level TF
prevalence levels, Fig 6A. In contrast, there was evidence of a strong negative correlation
between the specificity of TF for infection and the community prevalence of TF (r = -0.99, 95%
CI -0.99 to -0.96, p<0.0001), Fig 6B. The Forest plot of the post-treatment relationship between
disease and detection of infection at the individual level showed an overall strong association
(OR 8.38, 95% CI 7.09 to 9.90, p<0.0001), although there was marked heterogeneity (I2 = 75%,
p<0.001), Fig 4B. Although this overall OR is slightly higher post-MDA compared to pre-
MDA, it should be noted that this result is calculated from individual-level data, whereas the
correlations betweenTF and C. trachomatis infection prevalence (Fig 2) are calculated from
population-level data. Compared to the pre-MDA situation (Fig 5A), after the introduction of
MDA the individual level sensitivity was weaker (39.2% (30.9%, 48.2%) while specificity was
stronger (96.1% (89.6%, 98.6%), Fig 5B.
The community-level prevalence of Active Trachoma and the proportion of people with TF
who were infected with C. trachomatis (PPV) did not appear to be correlated (r = 0.16, 95%CI
-0.52 to 0.72, p = 0.65), Fig 6C. Finally, the proportion of people without TF who were not
infected with C. trachomatis (NPV) was high (>90%), across the limited range of community-
level prevalence of Active Trachoma in these studies, Fig 6D.
Discussion
It has long been observed that the relationship between the signs of Active Trachoma and the
detection of C. trachomatis infection at the individual level is not highly concordant [12]. Sur-
veys, including those in this review, consistently find that within endemic populations there
are many individuals with signs of disease who do not have detectable infection and conversely
there are people who do not meet the diagnostic criteria for Active Trachoma (TF or TI) who
do have detectable infection. Therefore, at the individual level, signs of infection cannot be
depended upon to determine which members of an endemic community have ocularC. tracho-
matis infection.
In a trachoma endemic population, the main reason for this mismatch between active dis-
ease and infection is probably the different time courses of the typical infection and disease epi-
sodes, outlined in the introduction and illustrated in Fig 1. In addition, it is also possible that
other factors contribute to this mismatch. Some individuals who have detectable infection but
do not meet the diagnostic criteria for TF may have a mild trachomatous follicular conjunctivi-
tis. Others may have previously acquired immunity and are able clear the infectionwithout
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developing any detectable inflammatory signs. Alternatively, a positive NAAT test for C. tra-
chomatis in a clinically normal individual could arise through cross-contamination during
sample collection or processing. Clinical signs similar to those of Active Trachoma can also
arise for other reasons, such as viral or bacterial infections, vernal conjunctivitis and hypersen-
sitivity reactions [26].
It is clear that clinical signs are not a reliable indicator for C. trachomatis at the individual
level. There is no point-of-care diagnostic test available for programmes to use to determine
which individual members of a community are infected, and who would therefore benefit from
targeted antibiotic treatment. Moreover, a strategy of testing everybody is not considered a
Fig 6. The relationship between the individual level presence of Active Trachoma (TF or TF/TI) and the
detection of C. trachomatis infection by community TF prevalence after the introduction of MDA. (a)
Sensitivity of TF for infection. (b) Specificity of TF for infection. (c) Positive Predictive Value (PPV) of TF for C.
trachomatis infection. (d) Negative Predictive Value (NPV) of TF for C. trachomatis infection. Data from 6
population-based studies, summarised in Table 2. The size of the circles reflects the sample size.
doi:10.1371/journal.pntd.0005080.g006
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practical option. Therefore, theWHO guidance and the standard practice is to conduct com-
munity-wide antibiotic distribution of the entire population of endemic districts.
Decisions around the initiation and cessation of trachoma control measures are based on
the prevalence of TF in children aged 1–9 years, determined through district level surveys, such
as those conducted by the Global Trachoma Mapping Project. District-wide antibiotic treat-
ment programmes and F&Emeasures to suppress transmission are initiated where the initial
prevalence of TF is10%. Below 10% TF the advice is to conduct sub-district level surveys. If a
sub-district has10% TFMDA and F&E are implemented. For sub-districts between 5% and
9.9% TF the guidance is to consider targetedMDA and F&Emeasures. For sub-districts<5%
noMDA is needed and implementation of F&E can be considered.
The dependence on the clinical signs of disease to guide programmatic decisions raises the
important question of how accurate these clinical signs are as a proxy measure for C. trachoma-
tis infection at the population level. This question is particularly relevant after the introduction
of MDA, when the association between clinical signs and infection prevalence at the population
level is weaker, and as we try to determine when elimination targets have been reached.
In this systematic review, we found that prior to the introduction of antibiotic treatment the
relationship between the community-level prevalence of TF in children correlated well with that
of infection. The prevalence of TF was usually slightly greater than that of infection. Therefore,
over a wide prevalence range, the community-level prevalence of TF in children is a reliable indi-
cator that broadly reflects the underlying population burden of infection. The association
between disease and infection for all ages was much weaker than that for children only; this sup-
ports the rationale for measuring TF in 1–9 year olds as the key indicator group for determining
the need of antibiotic. The prevalence of TI was less well correlated than TF with infection before
MDA, with the disease prevalence generally underestimating the level of infection.
At the individual level the utility of TF as a marker for infection is highly sensitive to the
underlying prevalence of TF. Both the sensitivity and PPV rise substantially with increasing TF
prevalence, and the specificity and NPV both drop. This sensitivity increase is therefore offset
by a corresponding decrease in the specificity of this test in high TF prevalence communities.
The usefulness of TF as an indicator of an individual’s infection status is dependent on both
the sensitivity and the specificity of the test; too low a sensitivity leads to C. trachomatis
infected individuals not receiving treatment, whereas too low a specificity leads to wasted
resources treating uninfected individuals. The PPV possibly gives the clearest indication of
where TF is useful as an indicator of an individual’s infection status; when the prevalence of TF
is low (~5–10%), TF will only indicate an estimated 10% probability that the individual has C.
trachomatis infection. This probability increases steadily with prevalence and once the commu-
nity prevalence reaches 30%, the estimated PPV is in the order of 50–70%. Thus, where the
population TF prevalence is above 30%, a positive TF diagnosis gives a 50–70% probability that
an individual will be C. trachomatis infected.
After the introduction of MDA the relationship between the community prevalence of TF
and chlamydial infection is less certain. Although the relationship betweenActive Trachoma
and C. trachomatis infection appears to remain strong at the individual level, the population-
level data suggests that post-MDA, Active Trachoma has a greater tendency to overestimate
the underlying population prevalence of C. trachomatis infection. Below the 10% TF level the
prevalence of infectionwas consistently low, and therefore below this level, TF prevalence
appears to be a goodmarker for infection having being brought under control. However, in the
studies where the prevalence of TF was above 10% after the introduction of MDA, the underly-
ing prevalence of C. trachomatis infectionwas much less predictable. In some settings TF prev-
alence persists at high levels despite relatively little infection being detected. There might be
several reasons for this observation. For example, if the loads of infection are substantially
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lower following the introduction of MDA these may not be so readily detected by diagnostic
tests. Other bacterial speciesmight also provoke a follicular conjunctivitis more readily in indi-
viduals previously infected with C. trachomatis [26]. However, whatever the explanation, it is
likely that in some settings, the prevalence of TF will underestimate the impact MDA has had
on the prevalence of C. trachomatis. This might lead to the on-going use of MDA after the
infection has been adequately controlled.
There is much less published data on the relationship betweenTI and infection following
the introduction of MDA. In general, the prevalence of TI appears to reduce more readily than
TF. A number of studies have investigated the relationship between the load of infection and
disease signs. These suggest that TI is particularly associated with high loads of infection [27].
Therefore, the decline in TI may reflect a shift to less intense infections. However, there were a
few studies in which the prevalence of TI was low, but the prevalence of infection remained
substantial.
We identified a reasonable number of studies reporting the community-level relationship
between disease and infection prior to treatment, over a wide TF prevalence range. There were,
however, fewer studies documenting the situation following the introduction of MDA, poten-
tially limiting the conclusions that can be drawn after MDA. However, there was generally less
detail in these reports about the individual-level relationship between clinical signs and infec-
tion. The studies came mostly from several East andWest African countries, providing reason-
able geographical coverage of the regions with the greatest trachoma burden. Standard WHO
definitions of disease were generally used and the large majority of studies used the same com-
mercially produced PCR assay, providing consistency across studies. However, there was some
methodological heterogeneity. The age groups reported varied; where possible we use the data
for children only in the meta-analysis to try to provide greater consistency between studies.
The sample sizes varied considerably (from 56 to 7817); we weighted our analyses to adjust for
size. The sampling methodology also varied considerably. The studies included were generally
population-based samples or surveys of the entire resident population of a defined area.
Overall, the use of TF prevalence to guide the decision to initiate MDA in previously
untreated districts appears to be reliable. In contrast, the situation following treatment is more
uncertain, calling into question the reliability of clinical signs for monitoring progress towards
the achievement of the elimination targets [28]. There are reports from hyperendemic regions
that have receivedmany rounds of high-coverageMDA that suggest that the prevalence of TF
can be recalcitrant, even when C. trachomatis infection appears to have been brought under
control. Therefore, contextually appropriate, cost-effective tests for C. trachomatis infection
that can be administered in low-resource settings, and used to estimate the infection prevalence
in a population-based sample, would be very helpful in guiding decisions around the cessation
of MDA. Such tests are anticipated to reduce the number of annual rounds of MDA required
and lead to the confirmation of trachoma control at an earlier stage.
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